NeurogesX Reports Third Quarter 20...(Short-term investments ...)

Date:11/6/2009

Short-term investments 8,516 14,071 Prepaid expenses and other current assets 776 412 Restricted cash 40 40 -- -- Total current assets 57,800 24,958 Property and equipment, net 380 468 Restricted cash 160 160 Other assets -- 4 --- --- Total assets $58,340 $25,590 ======= ======= Liabilities and Stockholders' Equity Current liabilities: Accounts payable $524 $370 Accrued compensation 1,221 1,039 Accrued license fees 1,213 -- Accrued research and development 190 1,067 Other accrued expenses 1,208 540 Deferred revenue 7,242 -- Notes payable - current portion 740 2,833 --- ----- Total current liabilities 12,338 5,849 Non-current liabilities: Deferred revenue 41,426 -- Notes payable - non-current portion -- 191 Deferred rent 332 276 --- --- Total non-current liabilities 41,758 467
'/>"/>

SOURCE NeurogesX Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)